



## **FOR IMMEDIATE RELEASE**

### **Axxam SpA enters into a collaboration agreement with Bayer HealthCare for the provision of Drug Discovery Services**

**July 21<sup>st</sup>, 2015** - Axxam SpA (Milan/Italy), a leading provider of discovery services has entered into a multi-year collaboration agreement with Bayer HealthCare (Bayer), a global pharmaceutical company. The aim of this collaboration is to provide high level services to support Bayer's strong commitment to discover new therapies for diseases with high unmet medical need.

The collaboration agreement signed today follows a very successful relationship between the two companies started more than ten years ago with the provision of cell-based and biochemical assays by Axxam amenable to use in ultra HTS systems.

The collaboration will leverage Axxam's strong expertise in assay development for genome derived targets, compound screening and hit-to lead support and will also provide Bayer access to Axxam's innovative assay technologies.

Stefan Lohmer, co-founder and Chief Executive Officer at Axxam, commented: "Axxam is very pleased to continue our excellent working relationship with Bayer. We see this new collaboration agreement as a further validation for our focus on science, interactive client collaborations and continuous investment in enabling screening technologies and talented people. We are looking forward to this latest collaboration with our colleagues at Bayer in order to set the ground for the development of novel therapies for the benefits of the patients".

*For more information about Axxam, or to speak with Dr. Lohmer, please contact Sabrina Corazza at +39 02 2105634 or [sabrina.corazza.sc@axxam.com](mailto:sabrina.corazza.sc@axxam.com).*

#### ***About Axxam SpA***

*Axxam SpA is a privately owned contract research and discovery company located at the Science Park Openzone in Bresso (Milan, Italy). The Company is a leading provider of integrated discovery services for the entire Life Sciences industries as: Pharmaceutical, Crop protection, Animal health, Cosmetics and Nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies including: assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need. More information is available at [www.axxam.com](http://www.axxam.com).*